Rheumatology - Innovations

The UAB Division of Clinical Immunology and Rheumatology investigates a variety of promising new therapeutic agents for use in the treatment of arthritis and related diseases. UAB was among the first academic centers in the country to employ some of the world’s most advanced treatments for arthritis, such as the TNF inhibitors infliximab and etanercept.

The Rheumatic Diseases Core Center (RDCC) at UAB unites UAB researchers from a broad range of specialties to promote the use of state-of-the-art methodologies to address questions in arthritis and musculoskeletal disease research with the ultimate goal of translating findings into optimal patient diagnosis and treatment.

For the past 21 years, investigators in the Division’s Arthritis Clinical Intervention Program have conducted studies of new therapeutic agents for the treatment of rheumatoid arthritis, lupus, osteoarthritis, and related conditions.